Immune-related adverse events with immune checkpoint blockade: a comprehensive review
详细信息 查看全文
- 作者：J.M. Michota ; b ; c ; 1 ; jean-marie.michot@gustaveroussy.fr" class="auth_mail" title="E-mail the corresponding author ; C. Bigenwalda ; 1 ; S. Champiatb ; M. Collinsd ; e ; F. Carbonneld ; e ; S. Postel-Vinayb ; A. Berdeloua ; A. Vargab ; R. Bahledab ; A. Hollebecqueb ; C. Massardb ; A. Fuereaa ; b ; V. Ribraga ; b ; A. Gazzahb ; J.P. Armandb ; N. Amellalb ; E. Angevinb ; N. Noelc ; e ; f ; g ; C. Boutrosa ; b ; c ; C. Mateusa ; b ; c ; C. Roberta ; b ; c ; J.C. Soriab ; A. Marabelleb ; O. Lambottec ; e ; f ; g
- 关键词：Immune-related adverse events ; Immune checkpoint blockade ; Cytotoxic T-lymphocyte-associated antigen 4 ; Anti-PD-1 antibody ; Tumour neoantigen
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：54
- 期：Complete
- 页码：139-148
- 全文大小：683 K
文摘
- •
Programmed cell death protein-1 and cytotoxic T-lymphocyte-associated antigen-4 have roles in self-tolerance and various auto-immune conditions.
- •
Tumour neoantigens and normal tissue antigens could be cross-reactive.
- •
A correlation between dysimmune toxicity and antitumoural efficacy is emerging.
- •
Steroids must be used with caution in routine practice to treat dysimmune toxicity.